Dyslipidaemia and cardiovascular risk in HIV infection

References

• Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. New Engl J Med 2003;348(8):702–10
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. New Engl J Med 2003;348(8):679–80
   PubMed Web of Science ®Google Scholar
• Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease – is there a link? Lancet 1997;350(9):430–6
   Google Scholar
• Constans J, Seigneur M, Blann A, et al. Chronic infections and coronary heart disease. Lancet 1997;350(9083):1030
   PubMedGoogle Scholar
• Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394(6696):894–7
   PubMed Web of Science ®Google Scholar
• Louie JK, Hsu LC, Osmond DH, et al. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994–1998. J Infect Dis 2002;186(7):1023–7
   PubMed Web of Science ®Google Scholar
• Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24(6):416–20
   PubMed Web of Science ®Google Scholar
• Constans J, Marchand JM, Conri C, et al. Asymptomatic atherosclerosis in HIV-positive patients: a case-control ultrasound study. Ann Med 1995;27(6):683–5
   PubMed Web of Science ®Google Scholar
• Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51–F58
   PubMed Web of Science ®Google Scholar
• Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32(1):130–9
   PubMed Web of Science ®Google Scholar
• Kereveur A, Cambillau M, Kazatchkine M, et al. Lipoprotein anomalies in HIV infections. Ann Med Interne (Paris) 1996;147(5):333–43
   PubMedGoogle Scholar
• Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999;100(7):700–5
   PubMed Web of Science ®Google Scholar
• Roberts AD, Muesing RA, Parenti DM, et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999;29(2):441–3
   PubMed Web of Science ®Google Scholar
• Ducobu J, Payen MC. Lipids and AIDS. Rev Med Brux 2000;21(1):11–7
   PubMedGoogle Scholar
• Qaqish RB, Fisher E, Rublein J, et al. HIV-associated lipodystrophy syndrome. Pharmacotherapy 2000;20(1):11–7
   Google Scholar
• Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361(9359):726–35
   PubMed Web of Science ®Google Scholar
• Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003;33(5):571–6
   PubMed Web of Science ®Google Scholar
• Carter VM, Hoy JF, Bailey M, et al. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2001;2(3):174–80
   PubMedGoogle Scholar
• Ioannidis JP, Trikalinos TA, Law M, et al. HIV lipodystrophy case definition using artificial neural network modelling. Antivir Ther 2003;8(5):435–41
   PubMed Web of Science ®Google Scholar
• Sadowinski-Pine S, Cabrera-Munoz ML, Valencia-Mayoral P, et al. Coronary arteriopathy associated with cardiomyopathy in an adolescent with AIDS. Bol Med Hosp Infant Mex 1992;49(9):605–9
   PubMedGoogle Scholar
• Park YD, Belman AL, Kim TS, et al. Stroke in pediatric acquired immunodeficiency syndrome. Ann Neurol 1990;28(3):303–11
   PubMed Web of Science ®Google Scholar
• Moriarty DM, Haller JO, Loh JP, et al. Cerebral infarction in pediatric acquired immunodeficiency syndrome. Pediatr Radiol 1994;24(8):611–2
   PubMed Web of Science ®Google Scholar
• Paton P, Tabib A, Loire R, et al. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993;144(3):225–31
   PubMedGoogle Scholar
• Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study. Circulation 2000;102(19):2335–40
   PubMed Web of Science ®Google Scholar
• Laurence J. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1960
   PubMedGoogle Scholar
• Anderson DW, Virmiani R. Emerging patterns of heart disease in HIV infection. Hum Pathol 1990;21:253–9
   PubMed Web of Science ®Google Scholar
• Patel RC, Frishman WH. Cardiac involvement in HIV infection. Med Clin (North Am ) 1997;80:1493–512
   Web of Science ®Google Scholar
• Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002;34(1): 55–63
   PubMed Web of Science ®Google Scholar
• Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002;162(2):433–8
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Stalenhoef AF. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk 2003;10(2):121–8
   PubMedGoogle Scholar
• Meng Q, Lima JA, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002;144(4):642–8
   PubMed Web of Science ®Google Scholar
• Lai S, Lima JA, Lai H, et al. Human immunodeficiency virus 1 infection, cocaine, and coronary calcification. Arch Intern Med 2005;165(6):690–5
   PubMed Web of Science ®Google Scholar
• Bharati S, Joshi VV, Connor EM. Conduction syndrome in children with AIDS. Chest 1989;96:406–13
   Google Scholar
• Koppel K, Bratt G, Schulman S, et al. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor- containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29(5):441–9
   PubMed Web of Science ®Google Scholar
• Eldor A. Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. Bailliere’s Clin Haematol 1998;11(2):475–95
   PubMedGoogle Scholar
• Laurence J, Mitra D, Steiner M, et al. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996;87(8):3245–54
   PubMed Web of Science ®Google Scholar
• Chi D, Henry J, Kelley J, et al. The effects of HIV infection on endothelial function. Endothelium 2000;7(4):223–42
   PubMed Web of Science ®Google Scholar
• Adamson DC, Dawson TM, Zink MC, et al. Neurovirulent simian immunodeficiency virus infection induces neuronal, endothelial, and glial apoptosis. Mol Med 1996;2(4):417–28
   PubMed Web of Science ®Google Scholar
• Huang MB, Khan M, Garcia-Barrio M, et al. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir Immune Defic Syndr 2001;27(3): 213–21
   Google Scholar
• Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Prog Cardiovasc Dis 2000;43(2):151–70
   PubMed Web of Science ®Google Scholar
• Sani MU, Okeahialam BN, Aliyu SH, et al. Human immunodeficiency virus (HIV) related heart disease: a review. Wien Klin Wochenschr 2005;117(3):73–81
   PubMed Web of Science ®Google Scholar
• Lewis W. AIDS cardiomyopathy: physiological, molecular, and biochemical studies in the transgenic mouse. Ann NY Acad Sci 2001;946:46–56
   PubMed Web of Science ®Google Scholar
• Twu C, Liu NQ, Popik W, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc Natl Acad Sci USA 2002;99(22):14386–91
   PubMed Web of Science ®Google Scholar
• Lewis W. Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy. Prog Cardiovasc Dis 2003;45(4):305–18
   PubMed Web of Science ®Google Scholar
• Thiebaut R, Dabis F, Malvy D, et al. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996–1998 [Groupe d’Epidemiologie Clinique du Sida en Aquitaine (GECSA)]. J Acquir Immune Defic Syndr 2000;23(3):261–5
   PubMedGoogle Scholar
• Weinroth SE, Parenti DM, Simon GL. Wasting syndrome in AIDS; pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 1995;4:76–94
   Google Scholar
• Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90(2):154–62
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74(5):1045–52
   PubMed Web of Science ®Google Scholar
• Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and acquired immune deficiency syndrome. Endocrin Rev 1996;17:518–32
   PubMed Web of Science ®Google Scholar
• Pirich C, Efthimiou Y, O'Grady J, et al. Apolipoprotein A and biological half-life of prostaglandin I2 in HIV-1 infection. Thromb Res 1996;81(2):213–8
   Google Scholar
• Kritz H, Efthimiou Y, Stamatopoulos J, et al. Association of lipoprotein(a), prostaglandin I(2) – synthesis stimulating plasma factor, biological half-life of prostaglandin I(2) and high-density lipoproteins in HIV-1 infection of different stages. Prostaglandins Leukotrienes Essent Fatty Acids 2000;63(5):309–14
   PubMed Web of Science ®Google Scholar
• Singh IP, Chopra AK, Coppenhaver DH, et al. Lipoproteins account for part of the broad non-specific antiviral activity of human serum. Antiviral Res 1999;42(3):211–8
   PubMed Web of Science ®Google Scholar
• Owens BJ, Anantharamaiah GM, Kahlon JB, et al. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest 1990;86(4):1142–50
   PubMed Web of Science ®Google Scholar
• Fernandez-Miranda C, Pulido F, Carrillo JL, et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin Chim Acta 1998; 274(1):63–70
   Google Scholar
• Crook MA, Mir N. Abnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it? Int J STD AIDS 1999;10(6):353–6
   PubMed Web of Science ®Google Scholar
• The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. New Engl J Med 2003;349:1993–2003
   Google Scholar
• Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353(9170):2093–9
   PubMed Web of Science ®Google Scholar
• Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23(1):35–43
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyper-lipidaemia, and insulin resistance. Lancet 1998;351(9119): 1881–3
   PubMed Web of Science ®Google Scholar
• Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001;276(40):37514–9
   PubMed Web of Science ®Google Scholar
• Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterol- regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 2002;16(12):1587–94
   Google Scholar
• Miserez AR, Muller PY, Barella L, et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS 2001;15(15):2045–9
   PubMed Web of Science ®Google Scholar
• Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999;84(6):1925–31
   PubMed Web of Science ®Google Scholar
• Christeff N, Melchior JC, De Truchis P, et al. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999; 13(16): 2251–60
   PubMed Web of Science ®Google Scholar
• Christeff N, Nunez EA, Gougeon ML. Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy. Ann NY Acad Sci 2000;917:962–70
   Google Scholar
• Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104(3):257–62
   PubMed Web of Science ®Google Scholar
• Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13(10):F63–F70
   PubMed Web of Science ®Google Scholar
• Meyer L, Rabaud C, Ziegler O, et al. Protease inhibitors, diabetes mellitus and blood lipids. Diabetes Metab 1998;24(6): 547–9
   PubMed Web of Science ®Google Scholar
• Vigouroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999;25(3):225–32
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13(13): 1659–67
   Google Scholar
• Brinkman K, Rosenbaum KR, Wang J. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of anti-retroviral-therapy-related lipodystrophy. Lancet 1999;354(9184): 1112–5
   Google Scholar
• Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34(5):649–57
   PubMed Web of Science ®Google Scholar
• Anon. BHIVA treatment guidelines 2003. http://www bhiva org/guidelines html 2005 July 1
   Google Scholar
• Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37(5):613–27
   PubMed Web of Science ®Google Scholar
• Currier JS. How to manage metabolic complications of HIV therapy: what to do while we wait for answers. AIDS Reader 2000;10(3):162–9
   PubMedGoogle Scholar
• Bergersen BM, Sandvik L, Bruun JN, et al. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004;23(8):625–30
   PubMed Web of Science ®Google Scholar
• Neumann T, Woiwoid T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV- infected patients: part I. Differences due to the acquisition of HIV-infection. Eur J Med Res 2003;8(6):229–35
   Google Scholar
• Neumann T, Woiwod T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV- infected patients – part III: age differences. Eur J Med Res 2004;9(5):267–72
   PubMed Web of Science ®Google Scholar
• Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34(10): 1396–405
   PubMed Web of Science ®Google Scholar
• Anon. ‘Switch’ studies for people with lipodystrophy. Proj Inf Perspect 2000(30):9
   Google Scholar
• Geletko SM, ZuWallack AR. Treatment of hyperlipidemia in HIV-infected patients. Am J Health-Syst Pharm 2001;58(7):607–14
   PubMed Web of Science ®Google Scholar
• Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13(7):805–10
   PubMed Web of Science ®Google Scholar
• Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31(5):1266–73
   PubMed Web of Science ®Google Scholar
• Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000;20(9): 1066–71
   Google Scholar
• Moyle GJ, Lloyd M, Reynolds B, et al. Dietary advice with or without pravastatin for the management of hypercholesterol- aemia associated with protease inhibitor therapy. AIDS 2001;15(12):1503–8
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002;30(1):26–31
   Google Scholar
• Fessel WJ, Follansbee SE, Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS 2002;16(13):1785–9
   Google Scholar
• Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001;45(12):3445–50
   PubMed Web of Science ®Google Scholar
• Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424–007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32(1):18–29
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, et al. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005;21(2):231–44
   PubMed Web of Science ®Google Scholar
• Mikhaildis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005;21(6):959–70
   PubMed Web of Science ®Google Scholar
• Henry K, Melroe H, Huebsch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998;352:1031–2
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin and fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155–68
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A, Sekhar RV, Jahoor F, et al. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of ‘systemic steatosis’. Curr Opin Lipidol 2004;15(1):59–67
   PubMed Web of Science ®Google Scholar
• Klein D, Hurley LB, Quesenberry Jr CP, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30(5):471–7
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17(17): 2479–86
   Google Scholar
• Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33(4):506–12
   PubMed Web of Science ®Google Scholar
• Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000;5(8):329–33
   PubMedGoogle Scholar
• Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360(9347):1747–8
   PubMed Web of Science ®Google Scholar